Vitamin Shoppe, Inc (NYSE:VSI) – Research analysts at Gabelli lowered their FY2017 earnings per share (EPS) estimates for Vitamin Shoppe in a note issued to investors on Thursday. Gabelli analyst D. Witkowski now anticipates that the specialty retailer will post earnings of $0.40 per share for the year, down from their previous forecast of $0.75. Gabelli also issued estimates for Vitamin Shoppe’s FY2018 earnings at $0.25 EPS, FY2019 earnings at $0.40 EPS and FY2020 earnings at $0.75 EPS.
Vitamin Shoppe (NYSE:VSI) last issued its quarterly earnings results on Wednesday, November 8th. The specialty retailer reported ($0.03) EPS for the quarter, missing the Zacks’ consensus estimate of $0.17 by ($0.20). Vitamin Shoppe had a positive return on equity of 6.17% and a negative net margin of 20.27%. The firm had revenue of $288.20 million for the quarter, compared to analyst estimates of $297.61 million. During the same period in the prior year, the firm posted $0.50 EPS. The business’s revenue was down 8.5% compared to the same quarter last year.
ILLEGAL ACTIVITY WARNING: This report was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/11/13/analysts-offer-predictions-for-vitamin-shoppe-incs-fy2017-earnings-vsi.html.
A number of other equities analysts have also weighed in on the company. Morgan Stanley set a $8.00 price objective on Vitamin Shoppe and gave the company a “hold” rating in a research note on Thursday, August 10th. Barclays PLC reduced their price objective on Vitamin Shoppe from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Thursday. Goldman Sachs Group, Inc. (The) reiterated a “sell” rating and set a $6.00 price objective (down previously from $13.00) on shares of Vitamin Shoppe in a research note on Thursday, August 10th. BidaskClub lowered Vitamin Shoppe from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Finally, TheStreet lowered Vitamin Shoppe from a “c-” rating to a “d” rating in a research note on Wednesday, August 9th. Four research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $5.00.
Shares of Vitamin Shoppe (NYSE:VSI) opened at $3.50 on Monday. Vitamin Shoppe has a 52-week low of $2.95 and a 52-week high of $26.60. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.34 and a current ratio of 2.07. The company has a market capitalization of $83.92, a PE ratio of 3.76 and a beta of 0.74.
Several institutional investors have recently made changes to their positions in VSI. Macquarie Group Ltd. purchased a new position in shares of Vitamin Shoppe in the 3rd quarter valued at about $101,000. BNP Paribas Arbitrage SA increased its stake in shares of Vitamin Shoppe by 2.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the specialty retailer’s stock valued at $108,000 after purchasing an additional 192 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of Vitamin Shoppe by 18.1% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 9,410 shares of the specialty retailer’s stock valued at $110,000 after purchasing an additional 1,440 shares in the last quarter. Wolverine Trading LLC purchased a new position in shares of Vitamin Shoppe in the 2nd quarter valued at about $131,000. Finally, UBS Asset Management Americas Inc. increased its stake in shares of Vitamin Shoppe by 17,041.4% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 11,999 shares of the specialty retailer’s stock valued at $140,000 after purchasing an additional 11,929 shares in the last quarter. Hedge funds and other institutional investors own 98.39% of the company’s stock.
In other Vitamin Shoppe news, Director John D. Bowlin purchased 40,000 shares of the business’s stock in a transaction that occurred on Friday, August 25th. The stock was purchased at an average price of $5.50 per share, for a total transaction of $220,000.00. Following the purchase, the director now directly owns 56,028 shares in the company, valued at $308,154. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.07% of the stock is owned by insiders.
About Vitamin Shoppe
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.
Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.